Selectively altering microbiota for immune modulation
The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
1. A method for enhancing efficacy of a therapy of a cancer in a human or animal patient, wherein the method comprises selective killing or reducing growth of a target bacterial or archaeal sub-population of microbiota using a guided Cas nuclease, thereby increasing the relative proportion of a sub-population of a second bacterial species in the microbiota, wherein the sub-population of the second bacterial species comprise Bifidobacterium, Prevotella , Lachnobacterium, Lachnospira, or Shigella , wherein the therapy comprises administration of an effective amount of an immune checkpoint inhibitor to the patient, wherein the immune checkpoint inhibitor is a PD-1 (Programmed Cell Death Protein 1 ) inhibitor or a PD-L1 (Programmed Death-Ligand 1 ) inhibitor; wherein the method comprises:
a. contacting the microbiota with an engineered nucleic acid sequence for producing a host modifying (HM) crRNA, and
b. producing the HM-crRNA in a host of the target sub-population, wherein the HM-crRNA is operable with the Cas nuclease in the host cell to form a HM-CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas system, and wherein the HM-crRNA comprises a sequence that is capable of hybridizing to a target sequence of the host cell to guide the Cas nuclease to the target sequence in the host cell, whereby the target sequence is modified by the HM-CRISPR/Cas system and the host cell is killed or growth of the target sub-population is reduced; and wherein increasing the relative proportion of the sub-population of the second bacterial species in the microbiota modulates immune cells in the patient, whereby the efficacy of the therapy is enhanced for treatment of the cancer in the patient.
2. The method of claim 1 wherein the microbiota comprises a mixed population of human gut microbiota bacteria of different species, and wherein the selective killing comprises selectively killing cells of one or more of the different species and sparing cells of the other species.
3. The method of claim 1 , wherein the immune checkpoint inhibitor is an antibody.
4. The method of claim 3 , wherein the immune checkpoint inhibitor is nivolumab, pembrolizumab, pidilizumab, durvalumab, or atezolizumab.
5. The method of claim 1 , wherein the microbiota is gut microbiota.
6. The method of claim 1 , wherein the sub-population of the second bacterial species comprise Bifidobacterium.
7. The method of claim 6 , wherein the sub-population of the second bacterial species comprise Bifidobacterium longum.
8. The method of claim 1 , wherein the cancer is non-small-cell lung cancer (NSCLC).
9. The method of claim 1 , wherein the sub-population of the second bacterial species comprise Prevotella.
10. The method of claim 1 , wherein the sub-population of the second bacterial species comprise Prevotella copri.
11. The method of claim 1 , wherein the Cas nuclease is endogenous to the host cell.
12. The method of claim 11 , wherein the Cas nuclease is a Type II Cas.
13. The method of claim 12 , wherein the HM-CRISPR/Cas system comprises an endogenous tracrRNA of the host cell.
14. The method of claim 12 , wherein the HM-CRISPR/Cas system comprises a tracrRNA, and wherein the tracrRNA is encoded by an engineered nucleic acid.
15. The method of claim 11 , wherein the sub-population of the second bacterial species comprise Bifidobacterium.
16. The method of claim 11 , wherein the sub-population of the second bacterial species comprise Prevotella.
17. A method for enhancing efficacy of a therapy of a cancer in a human or animal patient, wherein the method comprises increasing the relative proportion of a sub-population of bacteria comprising Prevotella , Lachnobacterium, Lachnospira, or Shigella in a microbiota of the patient by administering a bacterial transplant to the patient, wherein the therapy comprises administration of an effective amount of an immune checkpoint inhibitor to the patient, and wherein the immune checkpoint inhibitor is a Programmed Cell Death Protein 1 (PD-1) inhibitor or a Programmed Death-Ligand 1 (PD-L1) inhibitor, and wherein the method comprises administering a bacterial transplant comprising Prevotella , Lachnobacterium, Lachnospira, or Shigella to the patient; and wherein the increasing the relative proportion of the sub-population of bacteria in the microbiota of the patient modulates immune cells in the patient, whereby the efficacy of the therapy is enhanced for treatment of the cancer in the patient.
18. The method of claim 1 , wherein the immune cells comprise cells selected from CD8 +cells, tumor infiltrating lymphocytes (TILs), CD4 +cells, T reg cells and memory cells.
19. The method of claim 17 , wherein the immune cells comprise cells selected from CD8 +cells, tumor infiltrating lymphocytes (TILs), CD4 +cells, T reg cells and memory cells.
20. The method of claim 1 , wherein the immune cells are upregulated or expanded in the patient.
21. The method of claim 1 , wherein the second bacterial species is probiotic, commensal or symbiotic with the patient.
22. The method of claim 17 , wherein the bacterial transplant comprises Prevotella copri.